ArticleGlycoconjugate journal2026
3'-sialyllactose inhibits the migration and invasion of LPS-induced B16F10 mouse melanoma cells through inactivation of the NF-
Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma has a high mortality rate and is aggressive. The development, metastasis, and angiogenesis of melanoma have all been connected to toll-like receptor 4 (TLR4). However, signal transduction mediated by TLR4 for accelerating melanoma progression is fully unclear. Because of this, the current research has been carried out to explore drug candidate possibility using 3'-Sialyllactose (3'-SL). We investigated the inhibitory effect of 3'-SL on migration and invasion, which are associated with treatment difficulty and mortality. The suppression of matrix metalloproteinases 9 (MMP-9) expression and activity by 3'-SL in B16F10 murine melanoma cells and concurrently downregulated the MAPK signaling pathway involved in this regulation. Therefore, our results demonstrate that 3'-SL may be a good candidate for the development of therapeutic agents to suppress malignancy associated with metastasis and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.